Humanofort Bio-Chemical parameters  – Tables

The variations of total cholesterol from the plasma of the studied group, men, before and after 2 months of treatment with Humanofort (4 capsules/day).

Normal values: less than 200 mg/dl

Nr	Name	Initial (mg)	After 2 months	Variations	Observations
1	Olinescu Radu	275	254	– 24
2	Georgescu Ghe.	279	238	– 41
3	Teodoriu Alex.	243	211	– 33
4	Racu Constantin	254	223	– 31
5	Cristea Gheorghe	335	284	– 51
6	Comişel Virgiliu	253	203	– 50
7	Liuşnea Octav.	285	226	– 59
8	Lixandru Petre	201	191	– 10
9	Pană Gheorghe	224	204	– 20
10	Aldescu Viorel	224	207	– 17
11	Bartoş Emil	295	210	– 85
12	Pitea Simion	286	249	– 37
13	Teodorescu Emil	314	276	– 38
14	Agiu Marian	163	149	– 14
15	Alexandru Const.	199	193	– 6
16	Murariu Adi. Mariu	202	173	– 29
17	Ioniţă Gheorghe	191	184	– 7

Total, mg 4223 3675 – 548

Mean, mg 248,4 216 – 32,3

Conclusions: In all investigated men, older than 50 years, total cholesterol was higher than normal values. After treatment with Humanofort, in all men, total cholesterol has decreased, with a mean of 32 mg, towards physiological range.The decrease of cholesterol was higher as the initial values were more increased.

The variations of the total cholesterol in the plasma of the studied group, women, older women older than 50 years, before and after treatment with Humanofort (4 capsules/day for 2 months).

Normal values, less than 200 mg/dl

Nr	Name	Initial values	After Treatment	Variations
1	Olinescu Victoria	233	204	– 29
2	Ignat Aurica	270	215	– 55
3	Gheorghe Georgeta	364	315	– 49
4	Ghiuţă Monica	194	184	– 10
5	Melacrinos Floarea	243	213	– 30
6	Georgescu Floarea	331	285	– 46
7	Zaharia Florina	255	230	– 25
8	Stoenescu Antonela	268	183	– 85
9	Dundaru Georgeta	277	258	– 19
10	Teodoriu Aneta	245	229	– 16
11	Popa Rodica	254	212	– 42
12	Comişel Ecaterina	278	226	– 52
13	Stefanovici Iasmina	379	368	– 11
14	Pitea Ludovica	270	246	– 24
15	Teodorescu Maria	422	405	– 17
16	Ionescu Maria	198	174	– 24
17	Zamfirescu Georgeta	235	175	– 60
18	Vătăman Rodica	317	307	– 10	Tiroidectomie
19	Ghiuţă Oana	347	346	– 1
20	Burtan Mariana	221	207	– 14
21	Păun Aurica	250	232	– 18
22	Dănilă Ana	174	161	– 13
	Total, mg	6025	5375	– 650
	Mean , mg	274	244	29,5

Conclusions: With two exceptions, all women have increased initial values of total cholesterol. After treatment, the total cholesterol has decreased in all women with a mean of 29,5 mg for the entire lot. In 5 women with high initial cholesterol (cases 2,3,6,8,11,12), the decrease of cholesterol after treatment had a mean of 50 mg. In 3 women with initial cholesterol higher than 300 mg, the decrease after treatment was low, but all were in almost pathological conditions. But, anyway, in all women treated, cholesterol has decreased, with a trend towards the upper physiological range. Humanofort has induced a regulatory effect.

The variations of LDL Cholesterol in men, before and after treatment with Humanofort  (4 capsules/day for 2 months).

Normal values: less than 130 mg/dl

Nr	Name	Initial values	After Treatment	Variations
1	Olinescu Radu	175	149	– 26
2	Georgescu Gheorghe	203	158	– 45
3	Teodoriu Alexandru	174	140	– 34
4	Racu Constantin	99	116	– 17
5	Cristea Gheorghe	228	178	– 50
6	Comişel Virgiliu	176	131	– 45
7	Liuşnea Octavian	188	134	– 54
8	Lixandru Petre	116	127	– 11
9	Pană Gheorghe	160	134	– 26
10	Aldescu Viorel	146	114	– 32
11	Bartoş Ionel	177	105	– 72
12	Pitea Simion	201	153	– 48
13	Teodorescu Emil	238	187	– 51
14	Alexandru Constantin	90	74	– 16
15	Murariu Adi Marius	112	85	– 27
16	Ioniţă Gheorghe	107	87	– 20
	Mean value for 16 men	156.8

Mean value for 14 men: 145 mg. For all 14 men, LDL cholesterol has decreased after treatment with Humanofort with a mean of 39 mg

Conclusions: From a group of 16 men, the administration of Humanofort has decreased LDL cholesterol (bad cholesterol) in 14 subjects (89 %) with a mean of 39 mg. In 2 men, the administration of Humanofort induced a slight increase of 14 mg (mean) of LDL. In these 2 men, the initial values of LDL were decreased (mean 107 mg), as compared with that of the majority (mean 145 mg). Therefore, the administration of Humanofort triggered a trend towards normal range In 7 men, with high initial values of LDL, the administration of Humanofort has induced an impressive decrease of LDL more than 45 mg Again, a regulatory effect of Humanofort.

The variations of LDL cholesterol (bad cholesterol) in the plasma of women, before and after the administration of Humanofort (4 capsules/day for 2 months).

Normal values: less than 130 mg/dl

Nr	Name	Initial values	After Treatment	Variations
1	Olinescu Victoria	153	114	– 39
2	Ignat Aurica	127	89	– 38
3	Gheorghe Georgeta	258	198	– 60
4	Ghiuţă Monica	113	107	– 6
5	Melacrinos Floarea	141	119	– 22
6	Georgescu Floarea	218	180	– 38
7	Zaharia Florina	169	149	– 20
8	Dundaru Georgeta	182	176	– 6
9	Teodoriu Aneta	158	127	– 31
10	Popa Rodica	157	127	– 30
11	Comişel Ecaterina	183	141	– 42
12	Stefanovici Iasmina	305	265	– 40
13	Pitea Ludovica	164	142	– 22
14	Ionescu Maria	112	91	– 21
15	Zamfirescu Georgeta	138	88	– 50
16	Vătăman Rodica	218	211	– 7
17	Ghiuţă Oana	266	235	– 31
18	Burtan Mariana	144	119	– 25
19	Păun Aurica	180	147	– 33
20	Dănilă Ana	94	84	– 10

Total, mean (mg) 174 140,5 34

Conclusions: For all women investigated, The initial mean value of LDL cholesterol was 174 mg/dl, moderatedly increased as compared with normal values. From all group, only 4 women have normal initial values, while 5 women have LDL values higher than 200 mg/dl.

The administration of Humanofort has induced a definetly decrease of LDL cholesterol with a mean of 34 mg/dl In 10 women, the decrease of LDL cholesterol was higher than 35 mg. In 4 women with initial values of LDL higher than 200, the administration of Humanofort has induced a decrease od more than 40 mg. As in the case of men, the administration of Humanofort has induced an adaptative, regulator effect.

The variations of CARDIOVASCULAR RISK FACTORS according to the recommended studies of AETHNA-2000 PROGRAM for the group of men, before and after administration of Humanofort (4 caps/day for 2 months). The detailed interpretation of Risk Factors were presented after the table. The following Risk Factors were studied: Total Cholesterol/HDL (TC/HDL) and ApoLipoprotein B/ApoLipoprotein A-1 (ApoB/A)

Nr	Name	Initial CT/HDL ApoB/A	After CT/HDL ApoB/A	Variations CT/HDLApoB/A	Observ.
1	Olinescu Radu	3.4 0.73	2.9 0.62	-0.5 -0.11
2	Georgescu Gheorghe	5.6 0.83	4.3 0.57	-1.3 -0.26
3	Teodoriu Alexandru	5.8 1.29.	5.02 0.92	-0.8 +0.37
4	Racu Constantin	6.1 0.98	5.3 0.89	-0.8 -0.09
5	Cristea Gheorghe	6.7 1.14	6.5 0.82	-0.02 -0.32
6	Comişel Virgiliu	5.1 0.71	3.5 0.57	-1.6 -0.14
7	Liusnea Octavian	3.7 0.56	2.8 0.45	-0.9 -0.11
8	Lixandru Petre	5.0 0.89	3.8 0.59	-1.2 -0.30
9	Pană Gheorghe	5.3 1.11	4.4 0.75	-0.9 -0.35
10	Aldescu Viorel	6.05 1.16	5.9 1.08	-0.2 -0.08
11	Bartoş Ionel	3.5 0.68	2.5 0.40	-1.0 -0.28
12	Pitea Simion	5.1 0.73	4.4 0.75	-0.7 +0.02
13	Teodorescu Emil	6.3 1.31	4.5 0.44	-1.8 -0.57
14	Agiu Marian	4.4 0.76	4.4 0.74	0.0 -0.02
15	Alexandru Constantin	4.6 1.01	3.8 0.72	-0.8 -0.19
16	Murariu Adi Marius	3.06 0.52	2.4 0.76	-0.5 + 0.24
17	Ioniţă Gheorghe	2.6 0.38	2.3 0.53	-0.3 +0.15
	Mean, mg	4.84 0.84	4.04 0.80	-0.80

Humanofort Bio-Chemical parameters extensive Study

Cardiovascular Risk Factors: Recommended Limits for men – AETHNA-2000:

CV Risk Total Cholesterol/HDL ApoB/ApoA

Lowest (less than 10%) Less than 3.8 less than 0.69

Low (less than 27%) 3.9 – 4.7 0.70 – 0.90

Moderate (51 – 75 %) 4.8 – 5.9 0.95 – 1.22

High (76 – 89 %) 6.0 – 6.9 1.25 – 1.48

Highest (less than 90%) Higher than 7.0 Higher than 1.50

Conclusions: According to the limits mentioned above, in the group of investigated men (17), 4 men were within high risk range (cases 4,5,10,13) according to the first risk ratio, but according to the second, only 2 (cases 3 and 13). Anyway, even for mean ratios, the first risk factor) total cholesterol/HDL was more severe, as for entire group, the mean ratio was 4.84 /moderate), while for the second, Apo Lipoprotein (B/A), the mean ratio was 0.84 (low range)

The administration of Humanofort produced an impressive decrease, (100%), a clear-cut effect for the first risk factor, decreased with a mean of o.84. After treatment, for the entire group, only one case (nr.5) remained within highrisk range. The decreasing effect of Humanofort was effective for the entire group of men. In 5 cases (2,6,8,11,13), 31 % the decrease was higher than 1.0. For the second risk factor, Lipoproteins B/A, the decreasing effect of Humanofort was present in 12 men (70 %) in a wide range, while for 5 men (30 %), a slight increase, mean of (18) was noticed, without a possible correlation with their health condition.

The variations of the RISK FACTORS FOR CARDIOVASCULAR DISEASES for women, according to the recommendation of AETHNA-2000 PROGRAM, before and after the treatment with Humanofort (4 capsules/day for 2 months)

Nr	Name	Initial CT/HDL Apo B/A	After treatment CT/HDL Apo B/A	Variations CT(HDL Apo B/A	Obs
1	Olinescu Victoria	3.75 0.83	2.75 0.47	-1.0 -0.36
2	Ignat Aurica	3.03 0.35	2.15 0.56	-0.9 -0.26
3	Gheorghe Georgeta	4.85 0.72	3.76 0.73	-1.09 +0.01
4	Ghiuţă Monica	3.28 0.67	3.28 0.46	0.0 -0.21
5	Melacrinos Floarea	4.5 0.72	4.4 0.71	-0.1 -0.01
6	Georgescu Floarea	4.3 0.21	3.5 0.52	-0.8 + 0.31
7	Zaharia Florina	4.04 0.72	3.77 0.66	-0.27 -0.06
8	Stoenescu Antonela	7.4 0.58	5.3 0.95	-1,9 +0.37
9	Dundaru Georgeta	4.3 —	3.8 —	-0.5
10	Teodoriu Aneta	4.4 0.86	5.3 0.80	+0.7 -0.06
11	Popa Rodica	4.1 0.58	3.1 0.80	-1.0 +0.22
12	Comişel Ecaterina	4.5 1.15	3.9 0.79	-0.6 -0.36
13	Stefanovici Iasmina	8.3 1.49	6.8 1.21	-1.5 -0.21
14	Pitea Ludovica	3.0 0.44	3.07 0.52	+0.07 +0.08
15	Teodorescu Maria	6.1 2.57	4.6 0.76	-1.4 -1.81
16	Ionescu Maria	2.64 0.40	2.5 0.38	-0.14 -0.02
17	Zamfirescu Georgeta	2.85 0.52	3.24 0.76	+0.39 +0.24
18	Vătăman Rodica	4.17 0.70	4.37 0.90	+0.27 +0.20
19	Ghiuţă Oana	8.46 2.02	4.5 1.12	-4.0 -1.9
20	Burtan Mariana	4.1 0.98	3.2 0.52	-0.9 -0.46.
21	Păun Aurica	5.68 0.74	4.8 0.61	-0.88 -0.13
22	Dănilă Ana	5.11 —	4.6 0.86	-0.5 —
	Mean, mg	4.49 (20) 1.73	3.80 (20)1.02

CARDIOVASCULAR RISK FACTORS, limits recommended by AETHNA-2000 PROGRAM for women

CV RISK Total Cholesterol/HDL LipoProtein B/A

Lowest (less than 10%) Less than 2.9 Less than 0.47

Low (less than 27%) 3.0 — 3.6 0.49 – 0.60

Moderate: 51-75% 3.7 — 4.6 0.66 – 1.152

High 76-89% 4.7 – 5.6 0.92 – 1.16

Highest 90% Higher than 5.7 Higher than 1.17

Conclusions: In the Humanofort Bio-Chemical parameters study, the entire lot of investigated women, at the initial values, for the first ratio factor (CT/HDL) there were 4 with the highest risk (cases 8, 13, 15, 19). For the second ratio (LipoB/A), there were 4 with the highest risk (cases 12, 13, 15, 19); the last three were common. For moderate CV risk, for both ratios there were common 5 cases (1,3,5,21,22), the second ratio contained more (9 cases).

The administration of Humanofort decreased the first risk factor in 18 cases (82 %). In these 18 women (82%), the CT/HDL ratio decreased in the mean of 1.01, while for the 4 women, this factor increased with a mean of 0.92. The administration of Humanofort decreased the second risk factor Lipoproteins B/A in 12 women (60 %) with a mean of 1.3, while for the 6 women, this factor increased with a mean of 0.75. The odd variation (an increase of risk factors in three women (cases 14, 17, 18) is not related with the magnitude of risk factors, but rather for individual constitutions For both Cardiovascular risk factors, the administration of Humanofort induced a clear-cut effect, a variation towards the physiological range.

The variations of INSULIN in men, before and after administration of Humanofort  (4 capsules/day for 2 months).

Normal range: 2.60 — 25uU/ml

Nr	Name	Initial value	After Treatment	Variations
1	Olinescu Radu	4.70	9.81	+5.11
2	Georgescu Gheorghe	2.39	1.94	– 0.45
3	Teodoriu Alexandru	17.49	15.96	– 1.53
4	Racu Constantin	30.91	4.80	-25.11
5	Cristea Gheorghe	14.70	11.06	– 3.64
6	Comişel Virgiliu	4.49	2.51	– 1.98
7	Liuşnea Octavian	6.25	6.23	– 0.02
8	Lixandru Petre	27.50	9.66	– 19.94
9	Pană Gheorghe	10.03	9.57	– 0.06
10	Aldescu Viorel	7.26	16.66	+9.40
11	Bartoş Ionel	7.29	0.29	– 7.0.
12	Pitea Simion	4.49	3.00	– 1.49
13	Teodorescu Emil	3.10	4.04	+0.94
14	Agiu Marian	19.54	3.89	-15.65
15	Alexandru Constantin	11.53	2.90	– 9.63
16	Murariu Adi Marius	3.74	2.31	– 1.43
17	Ioniţă Gheorghe	6.03	3.73	– 2.30
	Mean, uU/ml	10.04	6.03

Conclusions: The administration of Humanofort in 17 men produced a decrease of insulin level in 14 men (82 %) with a mean of 5.18 uU/ml. In 3 men, an increased effect was noticed, with a mean of 5.15uu/ml. The decreasing effect produced by Humanofort was higher in 4 cases (4, 8, 14, 15), as the initial insulin levels were higher than the mean. In these particular cases the insulin concentration dropped with a mean of 17uu/ml.

The variations of INSULIN LEVEL in women, before and after the administration of Humanofort (4 caps a day for 2 months).

The normal range: 2.60 — 25uu/ml

Nr	Name	Initial value	After Treatment	Variations
1	Olinescu Victoria	5.62	3.38	– 2.24
2	Ignat Georgeta	7.20	6.77	– 0.43
3	Gheorghe Georgeta	10.50	15.10	+5.40
4	Ghiuţă Monica	9.61	10.05	+0.44
5	Melacrinos Floarea	8.78	12.87	+4.09
6	Georgescu Floarea	2.72	5.01	+2.29
7	Zaharia Florina	4.66	5.24	+0.58
8	Stoenescu Antonela	14.09.	14.69	+0.60
9	Dundaru Georgeta	5.64	5.92	+0.28
10	Teodoriu Aneta	7.86	3.76	– 4.10
11	Popa Rodica	1.52	31.67	+30.15
12	Comişel Ecaterina	27.91	8.20	-19.71
13	Stefanovici Iasmina	21.19	0.73	-19.46
14	Pitea Ludovica	4.56	2.96	– 2.40
15	Teodorescu Maria	2.74	1.04	– 1.70
16	Ionescu Maria	8.94	7.08	– 0.86
17	Zamfirescu Georgeta	4.69	5.71	+ 1.02
18	Vătăman Rodica	4.16	6.20	+ 2.04
19	Ghiuţă Oana	14.62	10.18	– 3.44
20	Burtan Mariana	3.85	3.82	– 0.03
21	Păun Aurica	12.40	16.21	+ 3.81
22	Dănilă Ana	6.09	7.36	+ 1.25
	Total mean, uu/ml	8.60	8.36

Conclusions: The administration of Humanofort in women produced widespread effects. In 10 women (45 %), the insulin level decreased with a mean of 4.44 uu/ml. But for the rest (55 %) an increase of the insulin was observed with a mean of 4.33 uu/ml. Contrarily, as compared with the investigated group of men, in the same conditions, the administration of Humanofort in women produced an apparent regulatory effect, as a function of the initial value and the health conditions. For example, in cases 12 and 13, with very high initial levels, the insulin concentration dropped spectacularly with approx. 19. 5uu/ml. A contrary effect was observed for case 11, as the initial level of insulin was below physiological range, but after the administration of Humanofort increased to an upper level of 32uu/ml. Therefore, the regulatory effect of Humanofort on the insulin level is emphasized in both men and women.

Humanofort Bio-Chemical parameters 

The variations of IGF (Insulin-like Growth Factor) or Somatomedin C in men, before and after the administration of Humanofort (4 caps a day for 2 months).

Normal values: 64 — 188ng/ml

Nr	Name	Initial	After Treatment	Variations
1	Olinescu Radu	153	143	– 10
2	Georgescu Gheorghe	182	186	+ 4
3	Teodoriu Alexandru	117	73.6	– 43.4
4	Racu Constantin	223	137	– 86
5	Cristea Gheorghe	104	144	+40
6	Comişel Virgiliu	175	118	– 57
7	Liuşnea Octavian	168	137	– 31
8	Lixandru Petre	171	168	– 3
9	Pană Gheorghe	239	206	– 33
10	Aldescu Viorel	347	256	– 91
11	Bartoş Ionel	188	119	– 69
12	Pitea Simion	142	114	– 28
13	Teodorescu Emil	111	116	+ 4
14	Agiu Marian	176	141	– 35
15	Alexandru Constantin	441	112	-329
16	Murariu Adi Marius	486	150	-330
17	Ioniţă Gheorghe	182	229	+ 47
18	Mihăescu Gheorghe	453	162	-291

Mean ng/ml 222.3 151 77.3 21

Conclusions: In the Humanofort Bio-Chemical parameters study a group of 18 men, there were 5 (29 %) with initial values of IGF higher than 200ng/ml. The administration of Humanofort produced a clear-cut decreasing effect with a mean of 77 ng/ml in 14 subjects /77 %). But the most spectacular effect of Humanofort was the regulatory, as in all 5 subjects with initial very high values, the concentration of IGF returned to the normal range. In three cases (25, 16, 18), after the administration of Humanofort, the level of IGF droped with 300 ng/ml

The variations of IGF (Insulin-like Growth Factor or Somatomedin C in women, before and after the administration of Humanofort (4 caps per day, for 2 months).

Normal values: 64 – 188 ng/ml

Nr	Name	Initial	After Treatment	Variations
1	Olinescu Victoria	437	89.1	– 347.9
2	Gheorghe Georgeta	436	99.6	– 336.4
3	Ghiuţă Monica	127	170	+ 43
4	Melacrinos Floarea	420	125	– 295
5	Georgescu Floarea	110	99	-. 11
6	Zaharia Florina	153	130	– 23
7	Stoenescu Antonela	193	128	– 65
8	Dundaru Georgeta	416	168	– 248
9	Teodoriu Aneta	98.3	39.3	– 59
10	Popa Rodica	184	145	– 39
11	Comişel Ecaterina	137	83.4	– 54
12	Stefanovici Iasmina	165	147	– 18
13	Pitea Ludovica	183	163	– 20
14	Teodorescu Maria	39.6	59.7	+ 20.1
15	Ionescu Maria	144	132	– 12
16	Zamfirescu Georgeta	110	96.6	– 10.4
17	Vătăman Rodica	129	162	+ 33
18	Ghiuţă Oana	149	200	+ 51
19	Burtan Mariana	109	154	+ 45
20	Păun Aurica	128	110	– 18
21	Dănilă Ana	397	76.1	– 320.9
	Mean ng(ml	203	122.7

Conclusions: In the , .group of 21 women there were 5 (24 %) with very high initial values of IGF. After the administration of Humanofort, the level of IGF decreased (as mean) from 203 to 122.7 ng/ml in 16 women. The spectacular effect of Humanofort was regulatory, as for cases 1,3,5, 9, 21, the level of IGF droped with more than 250 ng/ml

CLINICAL PROFILE OF THE INVESTIGATED SUBJECTS

Captions: CV = Cardio Vascular Diseases; DsLip = Dislpidemic affections; Liver = liver affections; VSH = Sedimentation Rate of Erythrocytes; HT = Hypertensive

Men

Nr	Name	Age years	CV	DsLip	Diabetes	Liver	VSH	Observ.
1	Olinescu Radu	74					2.5	Thyroid troubles
2	Georgescu Ghe.	65					5
3	Teodoriu Alexandru	75	Vasc. accident				11	CEA = 5.12
4	Racu Constantin	61	2 Infractus	Pres-ent	Present		42	Obesity, athero-sclerosis
5	Cristea Gheorghe	56	Cardiop.	Pres.	Present		15	Heart dis.
6	Comişel Virgiliu	68					4
7	Liuşnea Octav	66					5
8	Lixandru Petre	38					5	Arthrosis?
9	Pană Gheorghe	59				Hepatitis	5
10	Aldescu Viorel	57			Present		20	CEA = 2.6
11	Bartoş Ionel	68					9
12	Pitea Simion	75					23	Muscular affec.
13	Teodorescu Emil	68	Cardiop.		Present		9
14	Agiu Marian	49					10	CEA = 3.5
15	Alexandru Const.	59					15
16	Murariu Adi Mariu	71					10	CEA = 3.6
17	Ioniţă Gheorghe	59					5	CEA = 3.4, PSA =9
18	Mihăescu Ghe	67

Women

 

Nr	Name Age	CV	DisLip	Diabet	Liver–VSH	Observations
1	Olinescu Victoria 69	Cardiop.			7	Thrombocytosis
2	Ignat Anica 69	HT			12	CEA = 2.6
3	Gheorghe Gorgeta 69	Atheroscl.	Present		42	Obese, metab.troub
4	Ghiuţă Monica 65				11
5	Melacrinos Floare 73				Affec. 22	CEA = 2.8
6	Georgescu Floarea 83	HT			37	CEA = 1.94
7	Zaharia Florina 54				10
8	Stoenescu Antone 62				36	CEA = 3.53
9	Dundaru Georgeta 70			Present	40	Obese
10	Teodoriu Aneta 73	Vasc.acc.			32	CEA = 8
11	Popa Rodica 58				Affec 5	Hepatitis, CEA =6.8
12	Comişel Ecaterina 59	Cardiop.			38	Obsese, glaucoma
13	Stefanovici Iasmina 53		Present		40	Obese
14	Pitea Ludovica 71				23	Fibroma
15	Teodorescu Maria 65	HT	Present		25	Thyroid problems
16	Ionescu Maria 59				7
17	Zamfirescu George.63				10
18	Vătăman Rodica 49	HT	Present		10
19	Ghiuţă Oana 61				38	Thyroidectomia
20	Burtan Mariana 49				9
21	Păun Anica 57				6
22	Dănilă Ana 62	HT		Present	13	Obese, Osteoporosis

GENERAL CONCLUSIONS AFTER THE ADMINISTRATION OF HUMANOFORT

Parameter	Sex	Principal variation	Mean	Regulatory effect
Total cholesterol	Men Women	100% decrease 100% decrease	32.3 mg 29.5 mg	22% decrease 50 mg 23% decrease 50 mg
LDL cholesterol	Men Women	89% decrease 100% decrease	39 mg 34 mg	11% increase in subjects with low initial values 10% decrease 40 mg
Risk factors TC/HDL	Men Women	100% decrease (moderate, low) 82% decrease 23% decrease had highest risk, all reduced to moderate	0.84 1.01	4 cases with initial high risk were reduced to one 30% presented a slight increase or non-receptive
Apo B/A	Men Women	70% decrease 60% decrease	0.80 0.75	30% regulatory increase 40% regulatory increase
Insulin	Men Women	82% decrease 45% decrease 55% decrease	5.18 uU 4.44 uU 4.33 uU	In 4 cases the decrease was higher than 17 uU Regulatory variations within physiological range
IGF	Men Women	77% decrease (29% high values) 75% decrease (24% high values)	77 ng 80 ng	The increases were within physiological range

The administration of Humanofort induced a clear-cut variation of parameters investigated towards the physiological range. Generally, as the initial values were higher, the regulatory variations were also higher, mostly decrease; therefore, the regulatory effect of Humanofort was a function of the initial values parameters. The same effect was also noticed with other parameters investigated, but not presented above, such as triglycerides, Cortisol, 17 ketosteroids, as well as some immunological: CEA, PSA, and CRP (Protein C Reactive).

The interpretation of this study was performed by dr. Radu OLINESCU, Ph.D. Senior Scientist from the Clinical Hospital Fundeni, Department of Biochemistry, Bucharest and former Visiting Professor at Department of Nutrition, the University of Illinois at Urbana Champaign, USA.

Humanofort Bio-Chemical parameters